Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Pharmacology  




2 Legal status  




3 Use  




4 See also  




5 References  













NM-2201







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

NM-2201
Legal status
Legal status
  • DE: Anlage II (Authorized trade only, not prescriptible)
  • UK: Class B
  • US: Schedule I
  • Illegal in Sweden
    • Identifiers

    • Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate

    CAS Number
    PubChem CID
    ChemSpider
    UNII
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC24H22FNO2
    Molar mass375.443 g·mol−1
    3D model (JSmol)

    • FCCCCCN1C=C(C(OC2=C(C=CC=C3)C3=CC=C2)=O)C4=CC=CC=C41

    • InChI=1S/C24H22FNO2/c25-15-6-1-7-16-26-17-21(20-12-4-5-13-22(20)26)24(27)28-23-14-8-10-18-9-2-3-11-19(18)23/h2-5,8-14,17H,1,6-7,15-16H2

    • Key:PRGFSQYZCKCBQO-UHFFFAOYSA-N

    NM-2201 (also known as CBL-2201 and NA-5F-PIC[1]) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB1 and CB2 receptors with low nanomolar affinity.[2][3][4][5]

    Pharmacology[edit]

    NM-2201 acts as a full agonist with a binding affinity of 0.332 nM at CB1 and 0.732 nM at CB2 cannabinoid receptors.[6] It has been linked to serious adverse events in users.[7]

    Legal status[edit]

    NM-2201 is specifically banned in Sweden,[8] Germany (Anlage II),[9] and Japan[10] but is also controlled in many other jurisdictions under analogue laws.

    On May 30, 2018 the United States Drug Enforcement Administration, Department of Justice published a notice of intent to place NM-2201 and 4 other synthetic cannabinoids in schedule I of the Controlled Substances Act. This notice went into effect on June 29, 2018.[11]

    Use[edit]

    NM-2201 was linked to an incident in December 2015 where 25-30 people in Ocala, FL were taken to hospitals after experiencing seizures.[11]

    See also[edit]

    References[edit]

    1. ^ Pulver B, Fischmann S, Gallegos A, Christie R (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403. PMID 36346325.
  • ^ Kondrasenko AA, Goncharov EV, Dugaev KP, Rubaylo AI (December 2015). "CBL-2201. Report on a new designer drug: Napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate". Forensic Science International. 257: 209–213. doi:10.1016/j.forsciint.2015.08.023. PMID 26386336.
  • ^ "NM-2201". Cayman Chemical. Retrieved 9 July 2015.
  • ^ Namera A, Kawamura M, Nakamoto A, Saito T, Nagao M (2015). "Comprehensive review of the detection methods for synthetic cannabinoids and cathinones". Forensic Toxicology. 33 (2): 175–194. doi:10.1007/s11419-015-0270-0. PMC 4525208. PMID 26257831.
  • ^ Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Baranovsky A, Shafran Y (November 2014). "Synthetic cannabinoids as designer drugs: new representatives of indol-3-carboxylates series and indazole-3-carboxylates as novel group of cannabinoids. Identification and analytical data". Forensic Science International. 244: 263–75. doi:10.1016/j.forsciint.2014.09.013. PMID 25305529.
  • ^ Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE (2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi:10.1007/s11419-016-0320-2. PMC 4929166. PMID 27429655.
  • ^ Samra K, Boon IS, Packer G, Jacob S (April 2017). "black mamba". BMJ Case Reports. 2017: bcr–2016–218431. doi:10.1136/bcr-2016-218431. PMC 5534782. PMID 28433979.
  • ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara" [Cannabinoids are proposed to be classified as a health hazard] (in Swedish). Folkhälsomyndigheten (The Public Health Authority). Retrieved 9 July 2015.
  • ^ "Gesetz über den Verkehr mit Betäubungsmitteln Anlage II" [Law on the Traffic in Narcotics Annex II]. www.gesetze-im-internet.de (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved 24 October 2016.
  • ^ Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, et al. (January 2017). "In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201)". Forensic Toxicology. 35 (1): 20–32. doi:10.1007/s11419-016-0326-9. PMC 5342258. PMID 28286577.
  • ^ a b "2018 - Temporary Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA Into Schedule I". www.deadiversion.usdoj.gov. Retrieved 2018-06-15.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=NM-2201&oldid=1226847453"
    Categories: 
    ●1-Naphthyl compounds
     ●Organofluorides
     ●Designer drugs
     ●Indoles
     ●Carboxylate esters
     Hidden categories: 
    ●CS1 Swedish-language sources (sv)
     ●CS1 German-language sources (de)
     ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Drugs missing an ATC code
     ●Articles containing unverified chemical infoboxes
      


    ●This page was last edited on 2 June 2024, at 05:49 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki